Document is current
Any future updates will be listed below
-
Authors
Ali, Dalal S. https://orcid.org/0000-0002-5378-5548
Khan, Aliya A. https://orcid.org/0000-0003-3733-8956
Brandi, Maria Luisa https://orcid.org/0000-0002-8741-0592
- License Information
-
More Information
Article History
Received: 18 May 2024
Accepted: 26 June 2024
First Online: 15 July 2024
Compliance with ethical standards
:
: D.SA.: declares no conflict of interest. A.A.K.: declares no conflict of interest M.L.B.: Honoraria: Amgen, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB; Grants and/or speaker: Abiogen, Alexion, Amgen, Amolyt, Amorphical, Bruno Farmaceutici, CoGeDi, Echolight, Eli Lilly, Enterabio, Gedeon Richter, Italfarmaco, Kyowa Kirin, Menarini, Monte Rosa, SPA, Takeda, Theramex, UCB; Consultant: Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Echolight, Kyowa Kirin, Personal Genomics, UCB.
